DMAC
DiaMedica Therapeutics Inc
7.90$
+1.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.8% | -9.0% | +15.3% | -7.5% | -11.8% | -16.2% | -19.0% | +81.3% | +7.6% | -13.5% | -15.2% | |
| – | +12.1% | -11.5% | +15.9% | -7.7% | -12.1% | -16.1% | -16.9% | +80.9% | +7.8% | -13.6% | -15.4% | |
| – | +103.5% | -53.8% | +570.8% | -70.6% | -26.8% | -14.4% | +58.7% | -19.1% | +370.4% | -68.9% | +5.4% | |
| – | +13.8% | -12.1% | +16.2% | -7.1% | -12.1% | -17.7% | -17.3% | +84.2% | +8.3% | -14.3% | -15.2% | |
| – | +36,800.0% | +8.1% | -2.0% | -25.8% | -18.6% | +7.2% | -36.4% | +61.5% | -0.8% | -93.8% | -50.0% | |
| – | +23.6% | -6.2% | +16.0% | +35.1% | +23.4% | -13.3% | -11.8% | +26.2% | -3.0% | +11.1% | +14.0% | |
| – | +28.4% | -6.1% | +18.0% | +39.2% | +25.4% | -13.5% | -11.8% | +28.0% | -2.6% | +12.0% | +14.7% | |
| – | +3.8% | +3.6% | +16.3% | +2.0% | +1.0% | +1.9% | +2.9% | +0.9% | +2.8% | +2.7% | +0.9% | |
| – | +7.3% | -22.7% | +6.0% | +54.3% | -19.7% | +60.3% | -16.3% | +52.3% | -23.2% | +123.3% | -14.6% | |
| – | -8.2% | -9.2% | +15.2% | -10.2% | -15.1% | -16.6% | -20.0% | +90.0% | +8.7% | -15.8% | -18.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.3% | +12.3% | +0.2% | +0.1% | +0.3% | +15.5% | -5.3% | +14.5% | +0.2% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.